Disc Medicine (IRON) vs Prestige Consumer Healthcare (PBH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Disc Medicine (IRON) has outperformed Prestige Consumer Healthcare (PBH) over the past year, losing 12.3% versus a loss of 23.2%. Over five years, PBH leads with a -17.4% price change compared with -44.4% for IRON. Disc Medicine is the larger company by market cap ($2.38 billion vs $2.28 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IRON | PBH |
|---|---|---|
| Share price | $62.06 | $48.23 |
| Market cap | $2.38B | $2.28B |
| 1-day change | +2.12% | +0.75% |
| YTD return | -21.85% | -21.82% |
| 1-year return | -12.28% | -23.19% |
| 5-year return | -44.39% | -17.44% |
| P/E ratio (TTM) | — | 13.40 |
| Forward P/E | — | 9.49 |
| EPS (TTM) | $-6.58 | $3.60 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.09B |
| Revenue growth (YoY) | — | -4.31% |
| Net income (latest FY) | $-212.18M | $190.30M |
| Gross margin | — | 54.71% |
| Operating margin | — | 28.42% |
| Net margin | — | 17.48% |
| 52-week high | $99.50 | $71.07 |
| 52-week low | $40.00 | $42.62 |
| Distance from 52-week high | -37.63% | -32.14% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +66.24% | +40.58% |
| Average volume | 471.18K | 547.31K |
| Shares outstanding | 38.39M | 47.37M |
| Employees | 165 | 890 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IRON has outperformed PBH by 10.9 percentage points over the past year.
About Disc Medicine
IRON stock →Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.
Health Care · Biotechnology: Pharmaceutical Preparations · 165 employees
About Prestige Consumer Healthcare
PBH stock →Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare.
Health Care · Biotechnology: Pharmaceutical Preparations · 890 employees
IRON vs PBH FAQ
Which is bigger, Disc Medicine or Prestige Consumer Healthcare?
Disc Medicine (IRON) is larger, with a market capitalization of $2.38B compared with $2.28B for Prestige Consumer Healthcare (PBH).
Which stock has performed better over the past year, IRON or PBH?
IRON returned -12.28% over the past 12 months, compared with -23.19% for PBH (price return, excluding dividends). Past performance does not predict future results.
Are Disc Medicine and Prestige Consumer Healthcare in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.